Cellosaurus logo
expasy logo

Cellosaurus WM793 (CVCL_8787)

[Text version]
Cell line name WM793
Synonyms WM-793; WM 793; WML 793; WM793B; WM-793B; WM 793B; WM793b; WC00062
Accession CVCL_8787
Secondary accession CVCL_5414
Resource Identification Initiative To cite this cell line use: WM793 (RRID:CVCL_8787)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: Wistar Institute melanoma cell line collection.
Population: Caucasian.
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: D18S51: 11,14->14,15.
Derived from site: In situ; Skin; UBERON=UBERON_0002097.
Sequence variations
  • Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=16827748; PubMed=18632627; PubMed=23851445; PubMed=24576830; Cosmic-CLP; DepMap; Wistar).
  • Mutation; HGNC; 1773; CDK4; Simple; p.Lys22Gln (c.64A>C); ClinVar=VCV000485487; Zygosity=Homozygous (PubMed=23851445; Cosmic-CLP; DepMap; Wistar).
  • Mutation; HGNC; 9588; PTEN; Simple; p.Trp274Ter (c.821G>A); ClinVar=VCV001762511; Zygosity=Heterozygous (PubMed=23851445; Cosmic-CLP; DepMap).
HLA typing Source: PubMed=15592718
Class I
HLA-AA*01:01,29:01
HLA-BB*35:01,57:01
HLA-CC*04:01:01,06:02
Class II
HLA-DPDPB1*04:01,04:01
HLA-DQDQB1*03:01:01,03:01:01
HLA-DRDRB1*11:03:01,11:03:01

Source: PubMed=26589293
Class I
HLA-AA*01:01,29:01
HLA-BB*35:02,57:01
HLA-CC*04:01,06:02
Genome ancestry Source: PubMed=30894373

Origin% genome
African2.43
Native American0.27
East Asian, North4.02
East Asian, South1.29
South Asian5.85
European, North24.77
European, South61.38
Disease Cutaneous melanoma (NCIt: C3510)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_5239 (1205Lu)CVCL_A800 (WM793-P1N1)CVCL_A801 (WM793-P1N2)
CVCL_A802 (WM793-P1N3)CVCL_A803 (WM793-P2N1)CVCL_A804 (WM793-P2N2)
CVCL_A805 (WM793-P2N3)
Sex of cell Male
Age at sampling 37Y
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; ESTDAB; Genomics_Center_BCF_Technion; PubMed=27087056; Wistar

Markers:
AmelogeninX (Wistar)
X,Y (ATCC; Cosmic-CLP; ESTDAB; Genomics_Center_BCF_Technion; PubMed=27087056)
CSF1PO11
D1S165612,17
D2S44111
D2S133817,24
D3S135814,16
D5S81810,12
D7S82010 (ESTDAB)
10,12 (ATCC; Cosmic-CLP; Genomics_Center_BCF_Technion; PubMed=27087056; Wistar)
D8S117912,14
D10S124816
D12S39118,24
D13S3178,14
D16S53912
D18S5114,15
D19S43313,15
D21S1128,29
D22S104515,16
DYS39110
FGA20,21
Penta D13
Penta E5,12
TH016,8
TPOX8
vWA17

Run an STR similarity search on this cell line
Web pages https://web.archive.org/web/20141129125241/http://www.wistar.org:80/lab/meenhard-herlyn-dvm-dsc/page/melanoma-cell-lines-0
Publications

PubMed=4053039
Herlyn M., Thurin J., Balaban G.B., Bennicelli J.L., Herlyn D., Elder D.E., Bondi E., Guerry D. IV, Nowell P.C., Clark W.H. Jr., Koprowski H.
Characteristics of cultured human melanocytes isolated from different stages of tumor progression.
Cancer Res. 45:5670-5676(1985)

PubMed=2253310; DOI=10.1007/BF00046337
Herlyn M.
Human melanoma: development and progression.
Cancer Metastasis Rev. 9:101-112(1990)

PubMed=2068080; DOI=10.1073/pnas.88.14.6028
Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J.A., Kerbel R.S.
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression.
Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991)

PubMed=8342600
Juhasz I., Albelda S.M., Elder D.E., Murphy G.F., Adachi K., Herlyn D., Valyi-Nagy I.T., Herlyn M.
Growth and invasion of human melanomas in human skin grafted to immunodeficient mice.
Am. J. Pathol. 143:528-537(1993)

PubMed=8160777
Kobayashi H., Man S., MacDougall J.R., Graham C.H., Lu C., Kerbel R.S.
Variant sublines of early-stage human melanomas selected for tumorigenicity in nude mice express a multicytokine-resistant phenotype.
Am. J. Pathol. 144:776-786(1994)

PubMed=11123321; DOI=10.4049/jimmunol.166.1.432
Li J., Pereira S., Van Belle P., Tsui P., Elder D.E., Speicher D.W., Deen K., Linnenbach A., Somasundaram R., Swoboda R.K., Herlyn D.
Isolation of the melanoma-associated antigen p23 using antibody phage display.
J. Immunol. 166:432-438(2001)

PubMed=15592718; DOI=10.1007/s00262-004-0561-5
Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A., Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G., Garrido F.
High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.
Cancer Immunol. Immunother. 54:141-148(2005)

PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x
Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R., Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D., Dummer R.
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.
Pigment Cell Res. 19:290-302(2006)

PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235
Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R., Muthusamy V., King A.J., Flaherty K.T., Bosenberg M.W., Herlyn M., Nathanson K.L.
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
Cancer Res. 68:5743-5752(2008)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006
Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L., Borg A., Pawelec G., Guldberg P.
Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARbeta signaling.
Mol. Cancer Res. 11:1166-1178(2013)

PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625
Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L., Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A., Chapman P.B., Yaeger R., Taylor B.S., Schultz N., Berger M.F., Rosen N., Solit D.B.
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Cancer Res. 74:2340-2350(2014)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27087056; DOI=10.1038/srep24569
Haridas P., McGovern J.A., Kashyap A.S., McElwain D.L.S., Simpson M.J.
Standard melanoma-associated markers do not identify the MM127 metastatic melanoma cell line.
Sci. Rep. 6:24569-24569(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) ATCC; CRL-2806 - Discontinued
Coriell; WC00062 - Discontinued
Cell line databases/resources CLO; CLO_0009619
cancercelllines; CVCL_8787
Cell_Model_Passport; SIDM00973
Cosmic-CLP; 1299081
DepMap; ACH-000827
ESTDAB; ESTDAB-083
LINCS_LDP; LCL-1264
Anatomy/cell type resources BTO; BTO:0004612
Biological sample resources BioSample; SAMN03471791
BioSample; SAMN10987987
CRISP screens repositories BioGRID_ORCS_Cell_line; 343
Chemistry resources ChEMBL-Cells; CHEMBL4630605
ChEMBL-Targets; CHEMBL4630705
GDSC; 1299081
PharmacoDB; WM793_1664_2019
PubChem_Cell_line; CVCL_8787
Encyclopedic resources Wikidata; Q54994312
Experimental variables resources EFO; EFO_0002873
Gene expression databases ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM109043
GEO; GSM185202
GEO; GSM185203
GEO; GSM185204
GEO; GSM185205
GEO; GSM188235
GEO; GSM188265
GEO; GSM188324
GEO; GSM887738
GEO; GSM888833
GEO; GSM952587
GEO; GSM1670581
Polymorphism and mutation databases Cosmic; 686397
Cosmic; 886836
Cosmic; 928693
Cosmic; 972274
Cosmic; 1155266
Cosmic; 1155545
Cosmic; 1155567
Cosmic; 1238114
Cosmic; 1303078
Cosmic; 2159433
Cosmic; 2163810
IARC_TP53; 24995
LiGeA; CCLE_074
Progenetix; CVCL_8787
Proteomic databases PRIDE; PXD004343
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation06-Jun-2012
Last entry update30-Jan-2024
Version number38